JP2015515462A5 - - Google Patents

Download PDF

Info

Publication number
JP2015515462A5
JP2015515462A5 JP2015501731A JP2015501731A JP2015515462A5 JP 2015515462 A5 JP2015515462 A5 JP 2015515462A5 JP 2015501731 A JP2015501731 A JP 2015501731A JP 2015501731 A JP2015501731 A JP 2015501731A JP 2015515462 A5 JP2015515462 A5 JP 2015515462A5
Authority
JP
Japan
Prior art keywords
blood
pegylated
composition
subject
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015501731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015515462A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/030355 external-priority patent/WO2013142135A1/en
Publication of JP2015515462A publication Critical patent/JP2015515462A/ja
Publication of JP2015515462A5 publication Critical patent/JP2015515462A5/ja
Pending legal-status Critical Current

Links

JP2015501731A 2012-03-20 2013-03-12 輸血の有効性を高める方法 Pending JP2015515462A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613105P 2012-03-20 2012-03-20
US61/613,105 2012-03-20
PCT/US2013/030355 WO2013142135A1 (en) 2012-03-20 2013-03-12 Method of enhancing efficacy of blood transfusions

Publications (2)

Publication Number Publication Date
JP2015515462A JP2015515462A (ja) 2015-05-28
JP2015515462A5 true JP2015515462A5 (enExample) 2016-04-21

Family

ID=49223191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501731A Pending JP2015515462A (ja) 2012-03-20 2013-03-12 輸血の有効性を高める方法

Country Status (10)

Country Link
US (2) US8859499B2 (enExample)
EP (1) EP2827887A4 (enExample)
JP (1) JP2015515462A (enExample)
BR (1) BR112014023200A2 (enExample)
CL (1) CL2014002464A1 (enExample)
HK (1) HK1204267A1 (enExample)
IN (1) IN2014MN02089A (enExample)
MX (1) MX2014011186A (enExample)
WO (1) WO2013142135A1 (enExample)
ZA (1) ZA201407616B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
BR112014023200A2 (pt) 2012-03-20 2018-09-18 Albert Einstein College Of Medicine Of Yeshiva University uso de uma composição
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
JP6667438B2 (ja) * 2013-12-09 2020-03-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 老化に関連する状態を処置する方法及び組成物
US20170333566A1 (en) * 2014-11-14 2017-11-23 Aima Biotech Conjugated Proteins
WO2016083331A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP3096160B1 (en) * 2015-05-20 2020-02-26 Veoneer Sweden AB An fmcw vehicle radar system
US11096962B2 (en) 2015-05-28 2021-08-24 Nanobiotix Nanoparticles for use as a therapeutic vaccine
ES2902467T3 (es) 2015-06-15 2022-03-28 Univ Leland Stanford Junior TIMP2 para su uso en el tratamiento de afecciones asociadas al envejecimiento
WO2017083281A1 (en) * 2015-11-09 2017-05-18 Albert Einstein College Of Medicine, Inc. Method of ameliorating side effects of sickle cell disease treatments
WO2017103914A1 (en) * 2015-12-17 2017-06-22 Regentis Biomaterials Ltd. Ready for use organic solvent free compositions comprising protein-polymer conjugates and uses thereof
ES2975517T3 (es) 2016-04-28 2024-07-08 Alkahest Inc Fracciones de plasma como terapia para el cáncer de timo
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
CN117899111A (zh) 2017-04-26 2024-04-19 万能溶剂有限公司 用血浆和血浆制品治疗认知障碍和运动障碍的给药方案
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
EP3655019A4 (en) 2017-07-18 2021-04-21 Virtech Bio, Inc. BLOOD SUBSTITUTES INCLUDING HEMOGLOBIN AND METHODS OF MANUFACTURING
UA128648C2 (uk) 2018-10-26 2024-09-18 Алкахест, Інк. Застосування плазми крові та фракцій плазми для пом'якшення болю, поліпшення загоювання ран та післяопераційного відновлення
JP7773169B2 (ja) * 2021-02-24 2025-11-19 学校法人 中央大学 ポリオキサゾリン結合アルブミン、人工血漿増量剤及び出血ショックの蘇生液

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267269A (en) * 1980-02-05 1981-05-12 Baxter Travenol Laboratories, Inc. Red cell storage solution
JPS56139419A (en) * 1980-03-31 1981-10-30 Kuraray Co Ltd Erythrocytic preservative and erythrocytic pharmaceutical for preservation
JP2001517686A (ja) * 1997-09-26 2001-10-09 ユーエイビー リサーチ ファンデーション 抗原性を減弱させた血球および、その利用法
WO2000018418A2 (en) * 1998-09-25 2000-04-06 Oklahoma Medical Research Foundation Inhibition of erythrocyte sickling by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester
US6251927B1 (en) * 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
US6875423B1 (en) * 1999-09-21 2005-04-05 Marcos Intaglietta Methods for increasing peripheral blood circulation
JP5099951B2 (ja) * 1999-11-12 2012-12-19 バクスター・インターナショナル・インコーポレイテッド 副作用が減少されたヘモグロビン組成物
US6811778B2 (en) 2001-09-10 2004-11-02 Biopure Corporation Method for improving oxygen transport by stored red blood cells
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7144989B2 (en) * 2002-03-25 2006-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
US7521174B2 (en) * 2003-12-05 2009-04-21 Albert Einstein College Of Medicine Of Yeshiva University Universal red blood cells, methods of preparing same, and uses thereof
CA2588517A1 (en) * 2004-12-01 2006-06-08 Devgen N.V. 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family
WO2006135740A1 (en) * 2005-06-10 2006-12-21 Albert Einstein College Of Medicine Of Yeshiva University Pegylated hemoglobin and albumin and uses thereof
WO2007058678A2 (en) * 2005-06-10 2007-05-24 Albert Einstein College Of Medicine Of Yeshiva University Uses of pegylated albumin
EP2391341A4 (en) * 2009-01-30 2012-05-09 Cuthbert O Simpkins REVIVAL LIQUID
US8815297B2 (en) * 2009-03-31 2014-08-26 Duke University Modulation of beta 2 adrenergic receptors by inhibitors of EGLN3 or pVHL
LT2440239T (lt) * 2009-06-09 2017-12-11 Prolong Pharmaceuticals, LLC Hemoglobino kompozicijos
US20110189166A1 (en) * 2010-01-29 2011-08-04 John Boucher Methods of treating hemorheologic abnormalities in mammals
US20130231287A1 (en) * 2010-02-25 2013-09-05 Parimala Nacharaju Pegylated albumin polymers and uses thereof
BR112014023200A2 (pt) * 2012-03-20 2018-09-18 Albert Einstein College Of Medicine Of Yeshiva University uso de uma composição
US20170333566A1 (en) 2014-11-14 2017-11-23 Aima Biotech Conjugated Proteins

Similar Documents

Publication Publication Date Title
Li et al. Scaffold-facilitated locomotor improvement post complete spinal cord injury: Motor axon regeneration versus endogenous neuronal relay formation
JP2014520142A5 (enExample)
IL294463A (en) Methods for treating or preventing eye conditions
JP2011088927A5 (enExample)
NZ592837A (en) Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
EA201492021A1 (ru) Антительный состав
CN102406205B (zh) 牡蛎多糖果汁饮料
WO2008064299A3 (en) Methods of reducing porcine circovirus-associated disease outbreaks
JP2017505761A5 (enExample)
JP2012528890A5 (enExample)
JP2015515462A (ja) 輸血の有効性を高める方法
Lieder et al. Cardioprotection by post-conditioning with exogenous triiodothyronine in isolated perfused rat hearts and isolated adult rat cardiomyocytes
MX2018013476A (es) Composiciones para tratar trastornos acido-base.
RU2018123666A (ru) Способ лечения рака у млекопитающего, включая человека, с примененим деплеции метионина и аспарагина
JP2017522288A5 (enExample)
Kelly et al. TNF receptor 2, not TNF receptor 1, enhances mesenchymal stem cell-mediated cardiac protection following acute ischemia
JP2016513523A5 (enExample)
CN105400214A (zh) 一种使用透明质酸交联明胶制备止血棉的方法
Ali et al. HORMONAL INDUCTION OF OVARIAN CYCLICITY AND CONCEPTION RATE IN POSTPARTUM ANESTRUS BUFFALOES.
JP2017525704A5 (enExample)
Feng et al. Adaptive phenol-based hydrogel embedded with metformin nanoparticles targets oxidative stress and ferroptosis for spinal cord injury repair
Schmidt et al. Remote ischemic conditioning: the cardiologist's perspective
HK1200355A1 (en) Treatment of red blood cells
Kumar et al. Horn cancer in bovines and its management
WO2012075244A3 (en) Use of hemoglobin effectors to increase the bioavailability of therapeutic gases